{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-001769","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.721686+00:00","generated_at":"2026-06-10T05:22:54.233938+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexaria raises $1.57M in registered direct offering and private placement","bullets":["Gross proceeds of $1.57M from sale of 889,272 shares at $0.97, pre-funded warrants for 729,058 shares at $0.9699, and private placement warrants for 1,618,330 shares at $0.97.","Placement agent Maxim Group LLC receives 7% cash fee; offering closed October 3, 2023.","Net proceeds to be used for R&D studies, patent costs, and general working capital.","Officers and directors subject to 30-day lock-up from September 28, 2023.","Private placement warrants exercisable after 6 months, expire 5.5 years; pre-funded warrants exercisable immediately."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-001769","json":"https://secwatch.observer/filing/0001640334-23-001769.json","markdown":"https://secwatch.observer/filing/0001640334-23-001769.md","text":"https://secwatch.observer/filing/0001640334-23-001769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001769/0001640334-23-001769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001769/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T05:22:54.233938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df945bf7b6886c508bc32e798d19913ba4732d80","claim":"Lexaria Bioscience Corp. entered into SPA with a certain institutional investor valued at $1,569,780.10 (effective 2023-09-28).","evidence_excerpt":"On September 28, 2023, Lexaria Bioscience Corp., a Nevada corporation (the “Company”), entered into a securities purchase agreement (the “SPA”) with a certain institutional investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423001769/0001640334-23-001769-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Value","value":"$1,569,780.10"},{"label":"Effective","value":"2023-09-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}